Canclini M, Saviolo-Negrin N, Zanon E, Bertoletti R, Girolami A, Psychological aspects and coping in hemophilic patients: a case-control study. Hemophilia. 2003 Sep;9(5):619-24.
DiMichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002, 8, 280-287.
Hedner U, Glazer S. Management of hemophilia patients with inhibitors. Hematol Oncol Clin North Am. 1992 Oct;6(5):1035-46.
Gill JC. The role of genetics in inhibitor formation. Blood (United States), Aug 1999, 82(2) p500-4
Goodeve A., The incidence of inhibitor development according to specific mutations—and treatment? Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S17-21.
Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood (United States), Oct 1 2003, 102(7) p2358-63
Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Blood (United States), Jun 2002, 28(3) p285-90
Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV., Catalytic antibodies to factor VIII in haemophilia A. Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S31-4.
Nordfang, Mirella E Rasmussen, DK, Preparation for the treatment of hemophilia a inhibitor patients and a process for producing such a preparation. Biotechnol Adv. 1990;8(2):396.
Pandey GS, Panigrahi I, Phadke SR, Mittal B.
Knowledge and attitudes towards hemophilia: the family side and role of hemophilia societies. Community Genetics. 2003;6(2):120-2.
Shibata M, Shima M, Misu H, et al. Management of hemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Hemophilia, May 2003, 9(3) p269-71
Seremetis S., Dose optimization of recombinant factor VIIa in the reatment of acute bleeding in hemophilia-associated inhibitors. Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S29-30.